thassodotcom
Posted in Adverse Drug Reaction [ADR], New Safety Information, Rare Diseases, Thasso Post, Theragenomic Medicine
No Comments ↓
01 September 2018 – The American Food and Drug Administration (FDA) is warning that cases of a very rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors.
…
thassodotcom
Posted in Genetic Background, New Drug Approval, Rare Diseases, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
August 14, 2018 – The American Food and Drug Administration (FDA) just approved Patisiran (Onpattro) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], Allelic Variant, Genetic Susceptibility, In The Press, Personalized Medicine, Thasso Post, Theragenomic Medicine
No Comments ↓
thassodotcom
Posted in Allelic Variant, Companion Test, New Drug Approval, Personalized Medicine, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
July 22, 2018 – The American Food and Drug Administration (FDA) just approved Ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the IDH1 gene.
…
thassodotcom
Posted in New Drug Approval, Regulatory Approval, Thasso Post, Theragenomic Medicine
No Comments ↓
June 28, 2018 – The American Food and Drug Administration (FDA), a couple of week ago, approved Erenumab-Aooe (Aimovig) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Erenumab-Aooe 
(Aimovig) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.
…
thassodotcom
Posted in Genetic Background, Genetic Predisposition, New Drug Approval, Rare Diseases, Thasso Post, Theragenomic Medicine
No Comments ↓
June 26, 2018 – The American Food and Drug Administration (FDA) just approved Cannabidiol (Epidiolex), for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of epilepsy, in patients two years of age and older.
…
thassodotcom
Posted in Genetic Background, Genetic Predisposition, Thasso Post, Theragenomic Medicine
1 Comment ↓
Midway through the Soccer World Cup 2018 – Granted, the author of this article (that’s me) is addicted to soccer on several levels. For one, I have played football (same as soccer for the world outside the US) as a goal keeper myself; not at the highest performance levels,
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
3 Comments ↓
May 22, 2018 –The American Food and Drug Administration (FDA) just released a Safety Alert concerning serious neural tube defects that might arise in babies born to women who took HIV medications that contained the active ingredient Dolutegravir. Neural tube defects are birth defects that can occur early in pregnancy when the spinal cord,
…
thassodotcom
Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, New Research, On The Horizon, Thasso Post, Theragenomic Medicine
No Comments ↓
May 13, 2018 – Researchers have uncovered 17 genetic variants linked to different depression-related phenotypes in a large genome-wide association study, including variants near genes involved in neurotransmission and synapse function.
The first author of the study, David Howard, Center for Clinical Brain Sciences, University of Edinburgh,
…
Optional: Social Subscribe/Login
thasso: recent comments